Cancer trial aims to ditch harsh chemo for gentler immunotherapy
NCT ID NCT07177443
Summary
This large study is testing a new treatment plan for people with advanced nasopharyngeal cancer (a type of head and neck cancer). Researchers want to see if using an immunotherapy drug called serplulimab, along with a shorter course of chemotherapy, can control the cancer as well as the standard, more intensive treatment. The main goal is to see if this approach works just as well while potentially causing fewer side effects like severe vomiting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospital
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.